CARL ZEISS MEDI UNSP/ADR (CZMWY)
CZMWY moved a median of -0.21% 30 minutes after news, and -0.40% by the close. How CZMWY actually reacts to news — the realized, point-in-time move the market made, measured across 120 labeled events over the last three years with zero look-ahead.
CZMWY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 17% | 115 |
| 30-min | -0.21% | 21% | 119 |
| 60-min | -0.25% | 46% | 119 |
| to close | -0.40% | 41% | 119 |
| Middle 50% of CZMWY reactions | -0.56% to 0.00% |
|---|---|
| Median reaction (30-min) | -0.21% |
| Measured reactions | 120 |
Half of all CARL ZEISS MEDI UNSP/ADR news events land between -0.56% and +0.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CZMWY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CZMWY's baseline. Nothing else.
Recent CZMWY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| ZEISS demonstrates new digital and visual enhancements across ophthalmic workflows at AAO | Press release | Canada Newswire | +0.00% | -0.94% | |
| From diagnosis to treatment, ZEISS introduces innovations across ZEISS Retina Workflow at EURETINA 2026 | Press release | Canada Newswire | +0.00% | +0.70% | |
| ZEISS expands retinal imaging portfolio with new ZEISS ALTA DUO 300 | Press release | Canada Newswire | +0.00% | -2.15% | |
| ZEISS CLINIC 360 receives FDA 510k clearance, amplifying patient care through simplified clinical insights | Press release | Canada Newswire | +0.00% | +0.66% | |
| ZEISS announces strategic collaboration with Envision Health Technologies to advance glaucoma care with virtual reality-based function testing | Press release | Canada Newswire | -0.25% | +1.21% | |
| ZEISS Medical Technology and Aier Eye Hospital Group Sign Strategic Agreement for 25 VISUMAX 800 Units | Press release | Canada Newswire | +0.59% | -0.56% | |
| ZEISS announces successful early implantations of the AT LUCIA toric 721P intraocular lens | Press release | PR Newswire | +0.00% | +1.08% | |
| ZEISS expands ophthalmic surgical workflows in Mexico with COFEPRIS approval for ARTEVO 850 and MICOR 700 | Press release | Canada Newswire | -0.03% | -1.34% | |
| ZEISS advances connected cataract and refractive workflows with new digital, AI and surgical innovations at ASCRS | Press release | Canada Newswire | -0.14% | +1.06% | |
| ZEISS expands ophthalmic workflow portfolio in Canada with enhanced diagnostic, visualization and therapeutic solutions for precision eye care | Press release | Canada Newswire | +0.00% | +1.02% | |
| ZEISS launches Collaborative Care application to strengthen continuity of care; new solution offers on-premises and cloud-based options | Press release | PR Newswire | -0.46% | -0.51% | |
| ZEISS announces NMPA approval in China for powerful ophthalmic microscopes enhancing surgical visualization | Press release | PR Newswire | -0.05% | -1.04% | |
| ZEISS expands DORC portfolio and further strengthens digital footprint with improved workflow efficiency and digital visualization | Press release | PR Newswire | +0.40% | -0.92% | |
| ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones | Press release | Canada Newswire | +0.00% | +0.99% | |
| ZEISS showcases comprehensive workflow for full spectrum of retina care at EURETINA | Press release | Canada Newswire | +0.00% | +0.09% | |
| ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment | Press release | Canada Newswire | +0.04% | -1.07% | |
| ZEISS CLARUS 700 Receives NMPA Approval in China | Press release | PR Newswire | -0.13% | +0.56% | |
| ZEISS unveils AI-powered Research Data Platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care | Press release | Canada Newswire | +0.00% | +1.89% | |
| ZEISS continues to drive digital era forward in ophthalmology; celebrates 2 million digitally-planned cataract cases in the U.S. alone | Press release | Canada Newswire | +0.00% | -0.81% | |
| ZEISS receives FDA clearance for INTRABEAM 700 | Press release | PR Newswire | +0.00% | +9.18% | |
| ILM-Blue from DORC Receives NMPA Approval in China; Expanding Global Reach | Press release | PR Newswire | -2.45% | -1.80% | |
| ZEISS Introduces VISULAS Combi in Canada; a Revolutionary Therapeutic Laser Workstation for Enhanced Eye Care | Press release | Canada Newswire | — | -1.27% | |
| ZEISS VISUMAX 800 with SMILE pro software receives approval in China | Press release | Canada Newswire | -0.40% | -0.89% | |
| ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow | Press release | Canada Newswire | +0.00% | -0.04% | |
| ZEISS expands ophthalmic offerings to improve patient care with new digital AI tools and revolutionary surgical solutions | Press release | Canada Newswire | -0.06% | +2.55% | |
| ZEISS introduces its latest Robotic Visualisation System for neuro surgery | Press release | PR Newswire | -0.11% | -0.04% | |
| ZEISS reinvents lens extraction with the first hand-held ultrasound-free lens removal device, available in the U.S. | Press release | Canada Newswire | -0.30% | +0.24% | |
| ZEISS Redefines Disease Management and Treatment within the ZEISS Retina Workflow | Press release | Canada Newswire | +0.03% | -0.74% | |
| ZEISS innovation paves way to more personalized patient care with cutting-edge AI technology and industry-leading surgical solutions | Press release | Canada Newswire | -0.01% | -0.65% | |
| ZEISS announces OCT technology enhancements to better support growing era of data-driven patient care | Press release | PR Newswire | +0.00% | +0.27% | |
| Carl Zeiss Meditec AG Completes Acquisition of Dutch Ophthalmic Research Center (D.O.R.C.); Companies Unite to Shape Ophthalmology Market | Press release | PR Newswire | -0.08% | -0.40% | |
| ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024 | Press release | Canada Newswire | +0.00% | -2.28% | |
| U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS | Press release | PR Newswire | -0.01% | -0.38% | |
| Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.) | Press release | Canada Newswire | — | -1.36% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CZMWY section they belong to.
Where else CZMWY is measured.
CZMWY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | 121 | 0.00% | 38% |
| Avenue Therapeutics, Inc. (ATXI) | 120 | 0.00% | 37% |
| HEMP NATURALS INC (HPMM) | 120 | 0.00% | 37% |
| Marker Therapeutics, Inc. (MRKR) | 120 | -0.23% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is CARL ZEISS MEDI UNSP/ADR's median reaction calculated?
Every labeled CZMWY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 120 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 21% of CZMWY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CZMWY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.